Impedimed Share Price and Company Fundamentals
Last traded: Last Friday at 6:10 AM
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was incorporated in 1999 and is headquartered in Pinkenba, Australia.
|Primary activities||The development and sale internationally of medical devices for diagnosing and monitoring human disorders and diseases.|
|Industry / Sector||Medical Devices / Healthcare|
|Full time employees||73|
|Mailing address||50 Parker Court Unit 1 Pinkenba QLD 4008 Australia|
|Phone / Fax||61 7 3860 3700 / 61 7 3260 1225|
|Share registry||LINK MARKET SERVICES LIMITED|
Impedimed does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Impedimed.
|Mr. Richard Carreon||MD, CEO, Pres & Exec. Director||716.7k|
|Mr. David Michae Adams B.Sc., J.D., BSc||Sr. VP of Operations & Strategic Planning||460.79k|
|Mr. Shashi Tripathi||Chief Technology Officer||527.59k|
|Mr. Dennis Schlaht||Sr. VP of R&D and Technology||436.16k|
|Ms. Catherine Kingsford||Sr. VP of Medical Affairs||349.38k|
|Mr. Timothy Cruickshank||Chief Financial Officer|
|Mr. Michael John Bassett||Sr. VP of Corp. & Strategic Devel.|
|Ms. Nancy T. Deisinger||Sr. VP of HR|
|Dr. Frank A. Vicini FACR, M.D.||Chief Medical Officer|
|Ms. Leanne Ralph AAICD, ACIS, BBus||Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Impedimed is 164.49M and its enterprise value is 145.13M. The enterprise value to revenue ratio of IPD is 17.26.
The IPD's stocks Beta value is 3.01 making it 201% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Impedimed (IPD)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Impedimed (ASX:IPD) Frequently Asked Questions
1. What is Impedimed's Stock Symbol?
Impedimed trades on ASX under the ticker symbol "IPD".
2. What is Impedimed's stock price today?
One share of IPD stock can currently be purchased for approximately $0.11.
3. How can I contact Impedimed?
Impedimed's mailing address is 50 Parker Court Unit 1 Pinkenba QLD 4008 Australia. The company can be reached via phone at 61 7 3860 3700.
4. What is Impedimed's official website?
The official website of Impedimed is http://www.impedimed.com.
5. Which share registry manages Impedimed's stock?
Impedimed's stock is managed by LINK MARKET SERVICES LIMITED.